Cargando…

Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older

PURPOSE: This retrospective observational study investigated the efficacy and safety of vancomycin to treat patients aged 80 years and older. In particular, the associations between vancomycin trough concentration (VTC) and treatment outcomes or nephrotoxicity were explored. PATIENTS AND METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yunchao, Dai, Ning, Wei, Wei, Jiang, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179733/
https://www.ncbi.nlm.nih.gov/pubmed/34103905
http://dx.doi.org/10.2147/CIA.S308878
_version_ 1783703849122398208
author Wang, Yunchao
Dai, Ning
Wei, Wei
Jiang, Chunyan
author_facet Wang, Yunchao
Dai, Ning
Wei, Wei
Jiang, Chunyan
author_sort Wang, Yunchao
collection PubMed
description PURPOSE: This retrospective observational study investigated the efficacy and safety of vancomycin to treat patients aged 80 years and older. In particular, the associations between vancomycin trough concentration (VTC) and treatment outcomes or nephrotoxicity were explored. PATIENTS AND METHODS: Patients aged ≥80 years had received ≥3 vancomycin treatments and ≥1 detection of VTC. Treatment outcomes were defined as success or failure. Nephrotoxicity was considered an increase in serum creatinine ≥ 44.2 mmol/L, or 50% above baseline, for ≥2 consecutive days. Univariate and multivariate analyses were performed to identify risk factors for treatment failure and nephrotoxicity. RESULTS: Of 349 patients, 120 (34.4%) experienced treatment failure. For patients with VTCs at <10, 10–15, 15–20, and ≥20 µg/mL, the clinical response rates were, respectively, 77.8, 77.0, 80.5, and 61.0%; the 30-day mortality rates were 2.8, 15.0, 15.3, and 37.8%; and the rates of persistent bacteremia were 16.7, 12.4, 11.9, and 11.0%. The multivariate analysis indicated that blood urea nitrogen ≥11 g/dL and heart failure were independently associated with treatment failure; but not VTC (P = 0.004, 0.016, 0.828, respectively). During vancomycin treatment, 42 (12.0%) patients experienced nephrotoxicity with recovery time 7.5 ± 4.5 days. Fewer than half of patients with nephrotoxicity recovered after suspending vancomycin application. The variables found independently associated with increased nephrotoxicity were: VTC ≥15 µg/mL; treatment duration ≥15 d; and concomitant aminoglycosides administration (P = 0.024, 0.035, 0.029). CONCLUSION: In patients aged 80 years and older, elevated VTC level was not associated with favorable treatment outcomes. Patients with VTC ≥20 µg/mL appear to suggest a worsened prognosis compared with lower VTCs. The risk of nephrotoxicity increases with elevated VTC, longer treatment time, and concomitant aminoglycoside administration.
format Online
Article
Text
id pubmed-8179733
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81797332021-06-07 Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older Wang, Yunchao Dai, Ning Wei, Wei Jiang, Chunyan Clin Interv Aging Original Research PURPOSE: This retrospective observational study investigated the efficacy and safety of vancomycin to treat patients aged 80 years and older. In particular, the associations between vancomycin trough concentration (VTC) and treatment outcomes or nephrotoxicity were explored. PATIENTS AND METHODS: Patients aged ≥80 years had received ≥3 vancomycin treatments and ≥1 detection of VTC. Treatment outcomes were defined as success or failure. Nephrotoxicity was considered an increase in serum creatinine ≥ 44.2 mmol/L, or 50% above baseline, for ≥2 consecutive days. Univariate and multivariate analyses were performed to identify risk factors for treatment failure and nephrotoxicity. RESULTS: Of 349 patients, 120 (34.4%) experienced treatment failure. For patients with VTCs at <10, 10–15, 15–20, and ≥20 µg/mL, the clinical response rates were, respectively, 77.8, 77.0, 80.5, and 61.0%; the 30-day mortality rates were 2.8, 15.0, 15.3, and 37.8%; and the rates of persistent bacteremia were 16.7, 12.4, 11.9, and 11.0%. The multivariate analysis indicated that blood urea nitrogen ≥11 g/dL and heart failure were independently associated with treatment failure; but not VTC (P = 0.004, 0.016, 0.828, respectively). During vancomycin treatment, 42 (12.0%) patients experienced nephrotoxicity with recovery time 7.5 ± 4.5 days. Fewer than half of patients with nephrotoxicity recovered after suspending vancomycin application. The variables found independently associated with increased nephrotoxicity were: VTC ≥15 µg/mL; treatment duration ≥15 d; and concomitant aminoglycosides administration (P = 0.024, 0.035, 0.029). CONCLUSION: In patients aged 80 years and older, elevated VTC level was not associated with favorable treatment outcomes. Patients with VTC ≥20 µg/mL appear to suggest a worsened prognosis compared with lower VTCs. The risk of nephrotoxicity increases with elevated VTC, longer treatment time, and concomitant aminoglycoside administration. Dove 2021-06-01 /pmc/articles/PMC8179733/ /pubmed/34103905 http://dx.doi.org/10.2147/CIA.S308878 Text en © 2021 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Yunchao
Dai, Ning
Wei, Wei
Jiang, Chunyan
Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
title Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
title_full Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
title_fullStr Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
title_full_unstemmed Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
title_short Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
title_sort outcomes and nephrotoxicity associated with vancomycin treatment in patients 80 years and older
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179733/
https://www.ncbi.nlm.nih.gov/pubmed/34103905
http://dx.doi.org/10.2147/CIA.S308878
work_keys_str_mv AT wangyunchao outcomesandnephrotoxicityassociatedwithvancomycintreatmentinpatients80yearsandolder
AT daining outcomesandnephrotoxicityassociatedwithvancomycintreatmentinpatients80yearsandolder
AT weiwei outcomesandnephrotoxicityassociatedwithvancomycintreatmentinpatients80yearsandolder
AT jiangchunyan outcomesandnephrotoxicityassociatedwithvancomycintreatmentinpatients80yearsandolder